← Leaderboards
Longqin Hu
Rutgers The St Univ Of Nj New Brunswick
$3,572,091
Attributed
$5,011,514
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $621.1K · FY2005–21$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$5,011,514 · 7
By mechanism
R01$3,755,256 · 2
R21$1,016,723 · 3
R03$239,535 · 2
Top collaborators
- Amrik Sahota5 shared
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseInhibitor/AntagonistSulfhydryl CompoundsCysteineLeadEvaluationSafetyDoseBinding (Molecular Function)Small MoleculeAmidesComplexProteinsScreening ProcedureDisulfidesProgramsPharmaceutical PreparationsDesignProtein Protein InteractionKnockout MiceFutureBiological FactorsAdverse EffectsAffinity
Grant awards (18)
L-Cystine Diamides as Inhibitors of L-Cystine Stone Formation in Cystinuria$522,334
R01 · FY2021 · DK
L-Cystine Diamides as Inhibitors of L-Cystine Stone Formation in Cystinuria$523,106
R01 · FY2020 · DK
L-Cystine Diamides as Inhibitors of L-Cystine Stone Formation in Cystinuria$600,172
R01 · FY2019 · DK
L-Cystine Diamides as Inhibitors of L-Cystine Stone Formation in Cystinuria$612,089
R01 · FY2018 · DK
L-Cystine Diamides as Inhibitors of L-Cystine Stone Formation in Cystinuria$621,145
R01 · FY2017 · DK
HTS fluorescence polarization assay for inhibitors of Keap1-Nrf2 interaction$38,604
R03 · FY2012 · MH · contact PI
HTS fluorescence polarization assay for inhibitors of Keap1-Nrf2 interaction$46,431
R03 · FY2011 · MH · contact PI
Homogenous HTS Assays to Screen for Inhibitors of Keap1-Nrf2 Interaction$287,595
R01 · FY2010 · CA · contact PI
Optimization of EphA subtype-selective antagonists as probes for the nervous syst$250,148
R21 · FY2010 · AA · contact PI
Homogenous HTS Assays to Screen for Inhibitors of Keap1-Nrf2 Interaction$287,595
R01 · FY2009 · CA · contact PI
Optimization of EphA subtype-selective antagonists as probes for the nervous syst$252,675
R21 · FY2009 · AA · contact PI
Homogenous HTS Assays to Screen for Inhibitors of Keap1-Nrf2 Interaction$301,220
R01 · FY2008 · CA · contact PI
Novel Keap1-Nrf2 Inhibitors as Chemopreventive Agents$77,250
R03 · FY2008 · CA · contact PI
Novel Keap1-Nrf2 Inhibitors as Chemopreventive Agents$77,250
R03 · FY2007 · CA · contact PI
Structure-Based Design of Eph Receptor Antagonists$139,950
R21 · FY2005 · CA
Structure-Based Design of Eph Receptor Antagonists$139,950
R21 · FY2004 · CA
MECHANISM BASED INHIBITION OF CYCLIN DEPENDENT KINASES$117,000
R21 · FY2001 · GM
MECHANISM BASED INHIBITION OF CYCLIN DEPENDENT KINASES$117,000
R21 · FY2000 · GM